Cure Arthritis Naturally

Cure Arthritis Naturally

Get Instant Access

Alarcon-Segovia D, Tumlin J, Furie R, McKay J, Cardiel M, Linnik M, Hepburn B (2000) SLE trial shows fewer renal flares in LJP 394 treated patients with high-affinity antibodies to LJP 394: 90-05 trial results.Arthritis Rheum 43:S272 Anolik J, Campbell D, Ritchlin C, Holyst M, Rosenfeld S, Sanz I, Young F, Felgar R, Kunkel L, Benyunes M, Grillo-Lopez A, Rosenblatt J, Looney RJ (2000) PhaseI/II open-label, dose-escalation trial of rituximab (Rituxan) in patients with SLE. Arthritis Rheum 43:2860 Austin HA, Vaughan EM, Balow JE (2000) Lupus membranous nephropathy: randomized, controlled trial of prednisone, cyclosporine and cyclophosphamide. J Am Soc Nephrol 11:81A BallowM (1997) Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol 100:151-157 Beissert S, Luger TA (1999) Future developments of antipsoriatic therapy. Dermatol Therapy 11:104-117

Berner B, Scheel AK, Schettler V, Hummel KM, Reuss-Borst MA, Muller GA, Oestmann E, Leinenbach HP, Hepper M (2001) Rapid improvement of SLE-specific cutaneous lesions by C1q immunoadsorption. Ann Rheum Dis 60:898-899 Boehm IB, Boehm GA, Bauer R (1998) Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int 18:59-62

Caccavo D, Lagana B, Mitterhofer AP, Ferri GM, Afeltra A,Amoroso A, Bonomo L (1997) Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 40:27-35 Callen JP (1982) Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients. Arch Dermatol 118:412-416 Callen JP (2002) Management of skin disease in patients with lupus erythematosus. Best Pract

Res Clin Rheumatol 16:245-264 Carneiro JR, Sato EI (1999) Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 26:1275-1279 Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156-1162 Chandraratna RA (1997) Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol 37:S12-S17 Chang DM, Lan JL, Lin HY, Taipei LSF, Taiwan T (2000) GL 701 (prasterone, dehydroepiandro-sterone) significantly reduces flares in female patients with mild to moderate systemic lupus erythematosus (SLE). Arthritis Rheum 43:S241 Charles PJ, Smeenk RJT, de Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43:2283-2390 Conti F, Priori R, Alessandri C, Spinelli FR, Medda E,Valesini G (2000) Safety profile and causes of withdrawal due to adverse events in systemic lupus erythematosus patients treated long-term with cyclosporine A. Lupus 9:676-680 Dammacco F, Della Casa AO, Ferraccioli G, Racanelli V, Casatta L, Bartoli E (2000) Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythe-matosus. Int J Clin Lab Res 30:67-73 Daynes RA, Dudley DJ,Areano BA (1990) Regulation of murine lymphokine production in vivo. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells. Eur J Immunol 20:793-802 Delaporte E, Catteau B, Sabbagh N, Gosselin P, Breuillard F, Doutre MS, Broly F, Piette F, Ber-goend H (1997) Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases. Ann Dermatol Venereol 124:151-156 Dequet CR, Wallace, DJ (2001) Novel therapies in the treatment of systemic lupus erythematosus. Curr Opin Investig Drugs 2:1045-1053

Diamond B, Bluestone J,Wofsy D (2001) The immune tolerance network and rheumatic disease:

immune tolerance comes to the clinic. Arthritis Rheum 44:1730-1735 Duddridge M, Powell RJ (1997) Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 56:690-692 Dumont FJ (2002) IDEC-131. IDEC/Eisai. Curr Opin Investig Drugs 3:725-734 Edwards KR, Burke WA (1999) Treatment of localized discoid lupus erythematosus with tazarotene. J Am Acad Dermatol 41:1049-1050 Entani C, Izumino K, Iida H, Fujita M, Asaka M, Takata M, Sasayama S (1993) Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice. Nephron 64:471-475

Fautrel B, Foltz V, Frances C, Bourgeois P, Rozenberg S (2002) Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al. Arthritis Rheum 46:1408-1409 Ferrario L, Bellone M, Bozzolo E, Baldissera E, Sabbadini MG (2000) Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporin A. Rheumatology (Oxford) 39:218-220 Finck BK, Linsley PS, Wofsy D (1994) Treatment of murine lupus with CTLA4Ig. Science 265:1225-1227

Fleischmann M, Celerier P, Bernard P, Litoux P, Dreno B (1996) Long-term interferon-alpha therapy induces autoantibodies against epidermis. Dermatology 192:50-55 Frieling U, Luger TA (2002) Mycophenolate mofetile and leflunomide: promising compounds for the treatment of skin diseases. Clin Exp Dermatol 27:562-570 Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, Liebling MR, Hudson NP, Berner CM, Coutts S, de Haan HA (2001) Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 28:257-265 Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W (1999) Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 8:731-736 Gaubitz M, Seidel M, Kummer S, Schotte H, Perniok A, Domschke W, Schneider, M (1998) Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus. J Autoimmun 11:495-501 Geilen CC, Orfanos-Boeckel H, Offermann G, Orfanos CE (2000) Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses. Hautarzt 51:63-69 Genereau T, Chosidow O, Danel C, Cherin P, Herson S (1999) High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol 135:1124-1125 Goyal S, Nousari HC (2001) Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 45:142-144 Graninger M, Schmaldienst S, Derfler K, Graninger WB (2002) Immunoadsorption therapy

(therasorb) in patients with severe lupus erythematosus. Acta Med Austriaca 29:26-29 Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR (2000) Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 9:241-251

Haseley L, Wisnieski J, Denburg M, Michael-Grossman, AR, Ginzler EM, Gourley MF, Hoffman JH, Kimberly RP, Salmon JE (1997) Antibodies to C1q in systemic lupus erythematosus: Characteristics and relation to Fc-gamma RIIA alleles. Kidney Int 52:1375-1380 Hiepe F, Pfuller B, Wolbart K, Bruns A, Leinenbach HP, Hepper M, Schossler W, Otto V, (1999) C1q: a multifunctional ligand for a new immunoadsorption treatment. Ther Apher 3:246-251

Hsieh SC, Tsai CY, Sun KH,Tsai YY,Tsai ST, Han SH, Yu HS,Yu CL (1995) Defective spontaneous and bacterial lipopolysaccharide-stimulated production of interleukin-1 receptor antagonist by polymorphonuclear neutrophils of patients with active systemic lupus erythematosus. Br J Rheumatol 34:107-112 Huddlestone JR,Merigan TC Jr, Oldstone MB (1979) Induction and kinetics of natural killer cells in humans following interferon therapy. Nature 282:417-419

Jungers P, Nahoul K, Pelissier C, Dougados M, Tron F, Bach JF (1982) Low plasma androgens in women with active or quiescent systemic lupus erythematosus. Arthritis Rheum 25:454-457

Kitchin JE, Pomeranz MK, Pak G,Washenik K, Shupack JL (1997) Rediscovering mycophenolic acid:

a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 37:445-449 Kuhn A, Specker C, Ruzicka T, Lehmann P (2002) Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 46:600-603 Lafferty TE, Smith JB, Schuster SJ, DeHoratius RJ (1997) Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythe-matosus. Arthritis Rheum 40:775-778 Lagrange S, Piette JC, Becherel PA, Cacoub P, Frances C (1998) Sulfasalazine in the treatment of cutaneous lupus erythematosus: open trial in six cases. Lupus 7:21 Levy Y, Sherer Y, George J, Rovensky J, Lukac J, Rauova L, Poprac P, Langevitz P, Fabbrizzi F, Shoenfeld Y (2000) Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 29:321-327 Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM (1992) A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 326:1373-1379

Linker-Israeli M, Deans RJ,Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR (1991) Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 147:117-123

Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, Alcocer-Varela J, Grangeot-Keros L,Alarcon-Segovia D,Wijdenes J, Galanaud P, Emilie D (2000) Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43:1790-1800 Luger T (2001) Treatment of immune-mediated skin diseases: future perspectives. Eur J Dermatol 11:343-347

Manger K, Kalden JR, Manger B (1996) Cyclosporin A in the treatment of systemic lupus ery-

thematosus: results of an open clinical study. Br J Rheumatol 35:669-675 Matis LA, Rollins SA (1995) Complement-specific antibodies: designing novel antiinflammatories. Nat Med 1:839-842

McMurray RW (2001) Nonstandard and adjunctive medical therapies for systemic lupus erythematosus. Arthritis Rheum 45:86-100 McNeely PA, Iverson GM, Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, Lin-nik MD (2001) Pre-treatment affinity for LIP 394 influences pharmacodynamic response in lupus patients. Lupus 10:526-532 Mease PJ, Ginzler EM, Gluck OS, Schiff MH, Schmeer P, Gurwith M, Schwarz KE (2000) Improvement in bone mineral density in steroid-treated patients during treatment with GL 701 (prasterone, DHEA). Arthritis Rheum 43 (Suppl):206 Melez KA, Boegel WA, Steinberg AD (1980) Therapeutic studies in New Zealand mice. VII. Successful androgen treatment of NZB/NZW F1 females of different ages. Arthritis Rheum 23:41-47

Morton SJ, Powell RJ (2000) An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use. Ann Rheum Dis 59:487-489 Moxley G, Ruddy S (1997) Immune complexes and complement. In: Kelley WN, Harris ED, Ruddy S, Sledge CB (eds) Textbook of rheumatology, 5th edn. Saunders, Philadelphia, pp


Neuwelt CM, Al-Baude HA, Webb RL (1995) Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus. Am J Med 98:32-41 Nicolas JF, Thivolet J, Kanitakis J, Lyonnet S (1990) Response of discoid and subacute cutaneous lupus erythematosus to recombinant interferon alpha 2a. J Invest Dermatol 95:142S-145S Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M (2001) A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 44:S47-S57

Petera P, Manger B, Manger K, Rosenburg R, Smolen JS, Kalden JR (2000) A pilot study of leflunomide in systemic lupus erythematosus (SLE). Arthritis Rheum 43:S241 Petri M (2001) High dose Arava in lupus (HAIL). Arthritis Rheum 44:S280 Pfuller B, Wolbart K, Claunitzer A et al. (1998) Successful treatment of systemic lupus erythematosus by Clq-immunoadsorption. Arthritis Rheum 41:S110 Pisetsky DS (2000) Timor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 43:2381-2382 Prinz JC, Meurer M, Reiter C, Rieber EP, Plewig G, Riethmuller G (1996) Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412. J Am Acad Dermatol 34:244-252 Ramanujam M, Wang X, Ghosh SS, Huang W, Akkerman A, Roy-Chowdhury I, Davidson A (2002) Treatment of murine SLE using a double expressing CTLA4-Ig/ICOS-Ig adenovirus. Arthritis Rheum 46:S226

Rappersberger LE, Komar M, Ebelin ME, Scott G, Bueche M, Burtin P, Wolff K (2000) Oral SDZ ASM981: Safety, pharmacokinetics and efficacy in patients with moderate to severe chronic plaque psoriasis. J Invest Dermatol 114:776 Remer CF, Weisman MH, Wallace DJ (2001) Benefits of leflunomide in systemic lupus erythe-

matosus: a pilot observational study. Lupus 10:480-483 Riethmuller G, Rieber EP, Kiefersauer S, Prinz J, van der LP Meiser B, Breedveld F, Eisenburg J, Kruger K, Deusch K (1992) From antilymphocyte serum to therapeutic monoclonal antibodies: first experiences with a chimeric CD4 antibody in the treatment of autoimmune disease. Immunol Rev 129:81-104 Rodriguez-Castellanos MA, Rubio JB, Gomez JFB, Mendoza AG (1995) Phenytoin in the Treatment of Discoid Lupus Erythematosus. Arch Dermatol 131:620-621 Ronnblom LE, Alm G, Vberg KE (1990) Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 227:207-210

Rudnicka L, Szymanska E, Walecka I, Slowinska M (2000) Long-term cefuroxime axetil in sub-

acute cutaneous lupus erythematosus. A report of three cases. Dermatology 200:29-131 Rutter A, Luger TA (2002) Intravenous immunoglobulin: An emerging treatment for immunemediated skin diseases. Curr Opin Investig Drugs 3:713-719 Sauder DN, Wong D, Laskin C (1993) Epidermal cytokines in murine lupus. J Invest Dermatol 100:42S-46S

Schanz S, Ulmer A, Rassner G, Fierlbeck G (2002) Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 147:174-178 Schattner A (1988) Interferons and autoimmunity. Am J Med Sci 295:532-544 Schopf RE (2001) IDEC-114 (IDEC). Curr Opin Ivestig Drugs 2:635-638

Shou-Nee S, Fang FS, Yumei W (1987) Serum interferon in systemic lupus erythematosus. Br J Dermatol 117:155-159

Solsky MA, Wallace DJ (2002) New therapies in systemic lupus erythematosus. Best Pract Res

Clin Rheumatol 16:293-312 Strand V (2000) New therapies for systemic lupus erythematosus. Rheum Dis Clin North Am 26:389-405

Sturgess AD, Evans DT,Mackay IR, Riglar A (1984) Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus. J Clin Lab Immunol 13:11-14 Tebbe B, Lauy M, Gollnick H (1992) Therapy of cutaneous lupus erythematosus with recombinant interferon alpha-2a. Eur J Dermatol 2:253-255 Terman DS, Buffaloe G, Mattioli C, Cook G, Tillquist R, Sullivan M, Ayus JC (1979) Extracorpo-real immunoadsorption: initial experience in human systemic lupus erythematosus. Lancet 2:824-827

Theofilopoulos AN, Drummer W, Kono DH (2001) T cell homeostasis and systemic autoimmunity. J Clin Invest 108:335-340 Tomi NS, Luger TA (2003) The treatment of atopic dermatitis with topical immunomodulators. Clinics Dermatol 21:215-224

Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S, Baker S, Burt RK (2000) Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoi-etic stem-cell transplantation: a phase I study. Lancet 356:701-707 Viertel A, Weidmann E, Wigand R, Geiger H, Mondorf UF (2000) Treatment of severe systemic lupus erythematosus with immunoadsorption and intravenous immunoglobulins. Intensive Care Med 26:823-824

Vigano G, Gotti E, Casiraghi F,Noris M, Taddei I, Dionisio P, Remuzzi G (1995) Bindarit reduces urinary albumin excretion (UAB) and urinary interleukin 6 (IL-6) in patients with proliferative lupus nephritis. J Am Soc Nephrol 6:434 Walker SL, Kirby B, Chalmers RJ (2002) The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol 147:405 Wallace DJ (2001a) Apheresis for lupus erythematosus: state of the art. Lupus 10:193-196 Wallace DJ (2001b) Clinical and pharmacological experience with LJP-394. Expert Opin Inves-tig Drugs 10:111-117

Walport MJ, Davies KA, Botto M (1998) C1q and systemic lupus erythematosus. Immunobiology 199:265-285

Wu WM, Suen JL, Lin BF, Chiang BL (2000) Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice. Immunology 100:110-118 Yin Z, Bahtiyar G, Lanzhen L (2000) IL-10 down-modulates murine lupus. Arthritis Rheum 43:S438

Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F (2002) Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermato-myositis. Eur J Dermatol 12:50-52 Zoja C, Corna D, Benedetti G, Morigi M, Donadelli R, Guglielmotti A, Pinza M, Bertani T, Remuzzi G (1998) Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int 53:726-734

Was this article helpful?

0 0
Natural Arthritis Relief

Natural Arthritis Relief

Natural Arthritis Relief details a unique method of reversing Rheumatoid Arthritis Symptoms by removing numerous arthritis triggers as well as toxins using a simple 5 step natural process.

Get My Free Ebook

Post a comment